The invention discloses pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound with the structural formula (I). The experiments show that the gram-positive bacteria resisting effect of the pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound is equal or superior to that of moxifloxacin and ciprofloxacin, and particularly the clinical-drug and pan-drug resistant bacillus activity resisting of the pyrrolidine pyrazolyl oxo-quinoline carboxylic acid compound is quite strong.